Yet, with a second HBO treatment an opposite effect was evident at 72 h, with upregulated HMOX1, indicating an HBO/inflammation augmented ROS production [52], in addition to FGF18, IGF1 knock-down in Breast Cancer signaling [53] and p53 linked GADD45 and HES1 activation, both signifying reduced cell survival and apoptosis [54]. Here, TP53 is linked to breast carcinoma.